DRACO : Broad-Spectrum Antiviral Therapeutics - PLoS ONE
►http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022572
c’est le gros buzz en ce moment en recherche médicale : une nouvelle classe de médicaments #anti-viraux qui semble très prometteuse (et entièrement développée sur fonds publics)
We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including #dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 #influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which viruses have never encountered.